Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000518
Abstract: To date, cutaneous toxicities of combination therapies of anti-programmed death-1 (anti-PD1) and ipilimumab are poorly described. Understanding cutaneous presentations will aid clinicians with early diagnoses and treatments. We aim to describe and compare the cutaneous… read more here.
Keywords: combination; metastatic melanoma; patients metastatic; cutaneous toxicities ... See more keywords
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3076
Abstract: 3076Background: In advanced cancer, the overall response rate (ORR) following anti-PD1 monotherapy is variable (0% to 50%). Here, we hypothesized that this observation is partly explained by differ... read more here.
Keywords: pd1 monotherapy; anti pd1; response; association pd1 ... See more keywords